Drugs / Levobupivacaine
Levobupivacaine
also known as
Chirocaine · Levobupivacaine Hydrochloride · L-Bupivacaine · (s)-bupivacaine · (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride · Bupivacaine (-)-form · Bupivacaine (-)-form hydrochloride · Chirocaine 5 mg/ml - Levobupivacaine · +12 more
Other / unclassified targets SCN4A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CHIROCAINE | — | 1999-08-05 | fda.gov ↗ |
Trials 91 · started per year
today
US approved 1999
1
1
2
5
7
5
7
2
9
3
3
7
3
1
8
5
5
4
3
6
2
1
199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05559437 | Oct 2022 → Apr 2023 | hernia, double inguinal, neuropathy, painful | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT04221568 | Mar 2020 → Mar 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT04315454 | Jun 2019 → Dec 2020 | — | South Egypt Cancer Institute | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04113720 | Nov 2019 → Oct 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT07458204 | Oct 2026 → Oct 2031 expected | triple-negative breast carcinoma | Institut Jean-Godinot | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02796547 | Jul 2016 → May 2018 | — | Brugmann University Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01602250 | Jan 2011 → Aug 2013 | poisoning | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05145543 | Dec 2021 → Mar 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04209868 | Feb 2019 → Dec 2024 | chronic pain syndrome, neoplasm of thorax | Guy's and St Thomas' NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 311 trials · 1 met primary | ||||||
| Phase 3 | NCT06446960 | Feb 2024 → Sep 2026 overdue | stroke disorder | French National Institute of Health and Medical Research | Recruiting | No outcome recorded |
| Phase 3 | NCT05196256 | Jun 2022 → Jun 2023 | obstetric disorder | Brugmann University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05958589 | Jan 2022 → Jul 2024 | — | University of Novi Sad | Completed | No outcome recorded |
| Phase 3 | NCT04385966 | Feb 2020 → Oct 2021 | respiratory paralysis | Aragon Health Research Institute (IISAragon) | Completed | No outcome recorded |
| Phase 3 | NCT01994967 | Nov → Dec 2016 | vertebral column disorder | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02264834 | Jul 2014 → Mar 2018 | — | Dr Madeleine Wilwerth | Completed | No outcome recorded |
| Phase 3 | NCT02662660 | Jan 2012 → Dec 2015 | — | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 3 | NCT01458431 | Oct 2011 → Sep 2014 | — | Manuel Ángel Gómez-Ríos | Completed | Met primary |
| Phase 3 | NCT01184794 | Aug 2009 → Dec 2011 | — | Ashford and St. Peter's Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 3 | NCT00621907 | Mar 2008 → May 2009 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 3 | NCT00682344 | Jan 2008 → Jan 2012 | — | Assistance Publique Hopitaux De Marseille | Terminated | No outcome recorded |
| Phase 448 trials · 2 met primary · 3 missed | ||||||
| Phase 4 | NCT06695468 | Dec 2024 → Dec 2026 expected | cancer | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06567522 | Jun 2024 → Dec 2025 overdue | — | Hospital Álvaro Cunqueiro | Recruiting | No outcome recorded |
| Phase 4 | NCT06266767 | Feb → Oct 2024 | obstetric disorder, pain agnosia | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 4 | NCT06864312 | Oct 2023 → Jan 2025 | — | University College Cork | Completed | No outcome recorded |
| Phase 4 | NCT04773301 | Feb → Nov 2021 | bone disorder | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León | Completed | Missed primary |
| Phase 4 | NCT04697329 | Dec 2020 → May 2022 | — | Hospital Universitario de Móstoles | Completed | No outcome recorded |
| Phase 4 | NCT04397406 | Jul 2020 → Oct 2021 | — | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT04799184 | Apr 2019 → Aug 2021 | local anesthetic poisoning | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 4 | NCT03846102 | Jan 2019 → Feb 2020 | — | Zuyderland Medical Center | Terminated | Missed primary |
| Phase 4 | NCT03843970 | Jun 2018 → May 2023 | — | Hospital Clínico Universitario de Valencia | Unknown | No outcome recorded |
| Phase 4 | NCT02852720 | Dec 2016 → Feb 2017 | neuropathy, painful | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 4 | NCT03394807 | Oct 2016 → Jul 2017 | gallstones | Health Service Executive, Ireland | Completed | No outcome recorded |
| Phase 4 | NCT02689024 | May 2016 → Jul 2023 | — | Academic Medical Center - University of Amsterdam | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02557386 | Jan → Dec 2016 | — | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| Phase 4 | NCT02802683 | Sep 2015 → May 2016 | hypotensive disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02558569 | Sep 2015 → Aug 2016 | brain neoplasm | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT02293330 | Nov 2014 → Nov 2016 | toe, misshapen | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 4 | NCT02185716 | Jan 2014 → Jul 2015 | — | Duzce University | Completed | No outcome recorded |
| Phase 4 | NCT02025374 | Aug 2013 | — | Balikesir University | Completed | No outcome recorded |
| Phase 4 | NCT01886352 | Jun 2013 → Jun 2014 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT01938755 | Jun 2013 → Jan 2014 | — | Ordu University | Completed | No outcome recorded |
| Phase 4 | NCT04869046 | Mar → Dec 2013 | — | Mother and Child Health Institute of Serbia Dr Vukan Cupic | Completed | No outcome recorded |
| Phase 4 | NCT01785693 | Jan 2013 → Nov 2016 | peripheral arterial occlusive disease 1 | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT02035904 | Jan 2013 → Sep 2017 | chronic pain syndrome | Fondazione IRCCS Policlinico San Matteo di Pavia | Unknown | No outcome recorded |
| Phase 4 | NCT01597479 | Feb 2012 → Apr 2014 | — | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01596998 | Dec 2011 → Apr 2012 | — | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 4 | NCT02677532 | Dec 2011 → Nov 2013 | — | University of Genova | Completed | No outcome recorded |
| Phase 4 | NCT01389934 | Jul 2011 → Jan 2012 | — | Basque Health Service | Completed | No outcome recorded |
| Phase 4 | NCT01356797 | May → Sep 2011 | — | USP Hospital La Colina | Completed | No outcome recorded |
| Phase 4 | NCT02905695 | Jan 2011 → Jan 2015 | — | Hopital Foch | Completed | No outcome recorded |
| Phase 4 | NCT01560767 | Oct 2010 → Jul 2011 | osteoarthritis, knee | University of Warwick | Completed | No outcome recorded |
| Phase 4 | NCT01312077 | Oct 2010 → Jun 2011 | — | Cork University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01312415 | Aug 2010 → Jun 2011 | — | Cork University Hospital | Unknown | Met primary |
| Phase 4 | NCT01158586 | Apr → Sep 2010 | osteoarthritis, knee | United Christian Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00926666 | Oct 2009 → Apr 2011 | — | NHS Greater Glasgow and Clyde | Unknown | No outcome recorded |
| Phase 4 | NCT00970086 | Aug 2009 → Nov 2010 | local anesthetic poisoning | University Hospital, Basel, Switzerland | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01675895 | Jul 2009 → Jul 2011 | benign prostatic hyperplasia | Diskapi Teaching and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01199406 | Jul 2009 → Jan 2010 | cholecystolithiasis | Meander Medical Center | Completed | Missed primary |
| Phase 4 | NCT05829707 | Jan 2009 → Dec 2012 | chronic pain syndrome, female breast carcinoma | Osijek University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02322346 | Aug → Dec 2008 | — | Ankara University | Completed | No outcome recorded |
| Phase 4 | NCT00620477 | Jul 2008 → Nov 2010 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT02497040 | Mar 2008 → Mar 2009 | hypertensive disorder | Uludag University | Completed | No outcome recorded |
| Phase 4 | NCT04245774 | Nov 2007 → Aug 2008 | anus disorder | Gazi University | Completed | No outcome recorded |
| Phase 4 | NCT00929682 | Jun 2007 → Mar 2008 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT01881087 | Jun 2006 → Dec 2009 | — | Fundacion Clinica Valle del Lili | Completed | No outcome recorded |
| Phase 4 | NCT01229241 | Jul 2005 → Jun 2011 | — | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | Met primary |
| Phase 4 | NCT00836316 | — | cholelithiasis | Ege University | Completed | No outcome recorded |
| Phase 4 | NCT02465008 | ? → Jul 2016 | — | General University Hospital of Valencia | Suspended | No outcome recorded Stop: Enrollment |
| Phase not applicable23 trials · 2 met primary · 1 missed | ||||||
| — | NCT06926764 | Nov 2025 → Nov 2027 expected | — | Chinese University of Hong Kong | Not yet recruiting | No outcome recorded |
| — | NCT07084753 | Jul → Sep 2025 overdue | obesity disorder | IVO JURISIC | Not yet recruiting | No outcome recorded |
| — | NCT06611176 | Oct 2024 → Dec 2025 overdue | — | Laura Boer | Recruiting | No outcome recorded |
| — | NCT06176248 | Oct 2024 → Jan 2027 expected | frozen shoulder | Reims University Hospital | Recruiting | No outcome recorded |
| — | NCT06014957 | Aug → Dec 2023 | — | New Valley University | Unknown | No outcome recorded |
| — | NCT04941664 | Jan 2023 → Jul 2026 overdue | musculoskeletal system disorder | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| — | NCT05728151 | Feb 2022 → Apr 2024 | strabismus | Research Institute of Ophthalmology, Egypt | Completed | No outcome recorded |
| — | NCT04837742 | Apr 2021 → Jan 2023 | hepatocellular carcinoma | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT04773405 | Mar → Nov 2021 | musculoskeletal system disorder | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT05136625 | Feb 2021 → Jan 2024 | — | University Hospital of Ferrara | Unknown | No outcome recorded |
| — | NCT04294537 | Mar → Apr 2020 | appendicitis | Ospedale di Circolo - Fondazione Macchi | Unknown | No outcome recorded |
| — | NCT04000308 | Aug 2019 → May 2020 | pain agnosia | University Medical Centre Ljubljana | Completed | Met primary |
| — | NCT05034406 | May 2019 → May 2021 | varicocele | KBC Split | Completed | No outcome recorded |
| — | NCT04212611 | Mar 2019 → Jan 2020 | — | All India Institute of Medical Sciences, Rishikesh | Unknown | No outcome recorded |
| — | NCT03258697 | Oct 2017 → Jan 2019 | arthropathy | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT03302689 | Sep → Oct 2017 | neuropathy, painful | Alexandr Ronenson | Unknown | No outcome recorded |
| — | NCT04729868 | Apr 2017 → Apr 2020 | — | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT02677571 | Dec 2015 → Jan 2017 | — | Istituti Ospitalieri di Cremona | Completed | No outcome recorded |
| — | NCT02064088 | Nov 2013 → Nov 2015 | hydrocele | University Hospital, Montpellier | Unknown | Missed primary |
| — | NCT01856166 | Jun 2013 → Dec 2015 | pregnancy disorder | University Hospital, Montpellier | Completed | No outcome recorded |
| — | NCT02057601 | Jan → Jun 2013 | — | Cork University Hospital | Completed | No outcome recorded |
| — | NCT07285759 | Nov 2010 → Feb 2011 | staphylococcus aureus infection | Dokuz Eylul University | Completed | No outcome recorded |
| — | NCT05831761 | Sep 2009 → Oct 2011 | — | University Medical Centre Ljubljana | Completed | Met primary |
| Comparator or background therapy124 trials | ||||||
| Phase 0 | NCT04498351 Comparator | Jun 2020 → Sep 2021 | — | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT05600296 Comparator | Nov 2022 → May 2023 | — | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT03824314 Background | May 2019 → Jan 2020 | — | Mohamed Abdelrady Mohamed | Completed | No outcome recorded |
| Phase 1/2 | NCT03778671 Background | Jan → Nov 2019 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT06577155 Comparator | Aug 2024 → Jan 2025 | — | Asklepieion Voulas General Hospital | Completed | No outcome recorded |
| Show all 124 trials opens the full record — a long page | ||||||
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 217 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | levobupivacaine | “This double-blind, multicenter, randomized, controlled trial study was designed to compare the pharmacokinetics of continuous thoracic epidural infusion of levobupivacaine...” PMID 25977992 ↗ Aug 2015206“Dexmedetomidine (1 µg/kg) combined with 0.25% levobupivacaine (total volume 1 mL/kg) administered into the caudal epidural space over 60 seconds under general anesthesia, along...” NCT07852039 ↗ “Postoperative patient controlled epidural analgesia (epidural cathterer inserted into Th7-8 intervertebral space, 200 ml of 0.125% levobupivacaine, 4 mg of morphine, 0.075 mg...” NCT05831761 ↗ “A bilateral facial block (infraorbital and infratrochlear) will be performed immediately after intubation in patients undergoing outpatient rhinoplasty with 2.5%...” NCT01872728 ↗ “The study solutions were either 0.568 mg x ml(-1) levobupivacaine (low concentration group) or 1.136 mg x ml(-1) levobupivacaine (high concentration group), with sufentanil...” PMID 20565392 ↗ Jun 2010 “2.2 ml (11 mg) levobupivacaine (Chirocaine®, Abbott Laboratories, Ireland) was administered to patients with heights \<163 cm, while 2.4 ml (12 mg) levobupivacaine was...” NCT01858090 ↗ “At the end of surgery patients will receive bilateral ultrasound-guided single-shot TAP block: 0,15% levobupivacaine 0,75 mg/kg per side will be injected between internal...” NCT04294537 ↗ “The aim of this study was to analyze the costs and the efficiency of use of continuous infusion of levobupivacaine 0.5 % with the help of an infusion pump in modified radical...” PMID 26305021 ↗ Sep 2015 “The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml.” NCT01560767 ↗ “To evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries as regard:” NCT04729868 ↗ “Transforaminal epidural steroid injection (ESI TF) with corticosteroids like Methylprednisolone, Levobupivacaine and Lidocaine according to the protocol of the institution.” NCT06545812 ↗ |
| Known as | (s)-bupivacaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201193 ↗ |
| Known as | (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride | “Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride.” NCT04385966 ↗ |
| Known as | Bupivacaine (-)-form | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201193 ↗ |
| Known as | Bupivacaine (-)-form hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201193 ↗ |
| Known as | Chirocaine | “Name (INN and/or speciality) : Levobupivacaine (Chirocaine), 1.25 mg/ml Pharmaceutical form: Injectable Route of administration: Peri-Nervous Dosage for administration: 20ml...” NCT06446960 ↗16“The anaesthetic drug chosen for this study is levobupivacaine (Chirocaine™ -): it is S-isomer of bupivacaine, an amino-amide local anaesthetic widely used in regional anaesthesia” NCT03296189 ↗ “Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml).” NCT02385539 ↗ “1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) was added to 0.24 mL 50% Dextrose” NCT04245774 ↗ “Levobupivacaïne (Chirocaine®) is a new local anaesthetic recently marketed in France.” NCT00682344 ↗ “Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 40” NCT03956303 ↗ “Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)” NCT04729868 ↗ “Post-partum Perineal Pain - Chirocaine®” NCT02905695 ↗ “Chirocaine group (levobupivacaine )” NCT02037711 ↗ “Drug: chirocaine (Levobupivacaine)” NCT00621907 ↗ |
| Known as | Chirocaine 5 mg/ml - Levobupivacaine | “Chirocaine 5 mg/ml - Levobupivacaine” NCT01249872 ↗ |
| Known as | Chirocaine 5mg/ml, Abbot Laboratories, Greece | “Chirocaine 5mg/ml, Abbot Laboratories, Greece” NCT01558713 ↗ |
| Known as | ChirocaineR | “and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients.” NCT03189329 ↗ |
| Known as | Hirokain | “For TAP-block was used Hirokain® (Levobupivacaine) . Injectable solution 7.5 mg / ml” NCT03302689 ↗ |
| Known as | L-Bupivacaine | “Levobupivacaine group (L- bupivacaine 0,25% -2,5 mg/ml-) 60 ml. Total dosis in topical use 150 mg (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).” NCT02465008 ↗ |
| Known as | Levo-Bupivacaine Hydrochloride (HCl) | “Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection” NCT04209868 ↗ |
| Known as | Levob | “combined with Levobupivacaine (Levob) 0.125% (ED95% =125%=least effective concentration)” NCT03791879 ↗ |
| Known as | Levobupivac | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201193 ↗ |
| Known as | Levobupivacaina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201193 ↗ |
| Known as | levobupivacaine [Chirocaine, Abbott S.p.A., Italy] | “levobupivacaine [Chirocaine®, Abbott S.p.A., Italy]” NCT00860899 ↗ |
| Known as | Levobupivacaine HCl | “Group Levobupivacaine Bolus received 0.5 mg/kg 0.5% Levobupivacaine HCl every 8 h via wound catheter.” NCT05829707 ↗ |
| Known as | Levobupivacaine Hydrochloride | “Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration.” NCT04385966 ↗9“Patient had periarticular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement.” NCT03258697 ↗ “Levobupivacaine (as Levobupivacaine Hydrochloride) 75 Mg/10 mL Solution for Injection Ampoule” NCT04245774 ↗ “Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%” NCT02699827 ↗ “Levobupivacaine Hydrochloride 0.25 % Injectable Solution” NCT06369870 ↗ “plain levo-bupivacaine hydrochloride 0.5% intrathecally” NCT01582607 ↗ “Levobupivacaine Hydrochloride 1.25 MG/ML” NCT06446960 ↗ “Levobupivacaine Hydrochloride 2.5 MG/ML” NCT03785041 ↗ |
| Known as | Levobupivacaine Hydrochloride 5MG/ML | “Levobupivacaine Hydrochloride 5MG/ML” NCT03785041 ↗ |
| Known as | Levobupivacaine: Chirocaine, Abbott, Chicago, IL, USA. | “Levobupivacaine: Chirocaine®, Abbott, Chicago, IL, USA.” NCT01860521 ↗ |
| Known as | Novabupi | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201193 ↗ |
| Action | Inhibit | “its ability to block peripheral nociceptor transmission after tissue damage” NCT04113720 ↗1“Sodium channel protein type IV alpha subunit blocker” CHEMBL1201193 ↗ |
| Modality | Other / unclassified | “local anesthetic” NCT00926666 ↗ |
| Route | Other | “The addition of clonidine to epidural levobupivacaine and sufentanil for patient-controlled epidural analgesia in labour improved analgesia, reduced the supplementation rate...” PMID 20299988 ↗ May 2010 |
| Target | SCN4A | “Sodium channel protein type IV alpha subunit blocker” CHEMBL1201193 ↗ |